Literature DB >> 17203210

Newer vascular targets: endosialin (review).

Beverly A Teicher1.   

Abstract

The identification of cell surface markers expressed selectively by tumor vasculature is challenging. To get as close to the human disease as possible, investigators have isolated endothelial cells from fresh human tumor specimens and subjected them to RNA-based gene expression analysis. The data indicate that there are few proteins that distinguish tumor vasculature from normal vasculature and re-enforce the notion that the endothelium is a tissue specialized cell-type. Endosialin was identified as a cell surface tumor endothelial marker. The selective expression of endosialin by tumor vasculature and stroma has been confirmed. Although the function of endosialin remains to be elucidated, the expression pattern for this protein may be favorable for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17203210

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  11 in total

1.  Rapid isolation of high-affinity human antibodies against the tumor vascular marker Endosialin/TEM1, using a paired yeast-display/secretory scFv library platform.

Authors:  Aizhi Zhao; Selene Nunez-Cruz; Chunsheng Li; George Coukos; Don L Siegel; Nathalie Scholler
Journal:  J Immunol Methods       Date:  2010-09-15       Impact factor: 2.303

2.  Development of 124I immuno-PET targeting tumor vascular TEM1/endosialin.

Authors:  Ann-Marie Chacko; Chunsheng Li; Madhura Nayak; John L Mikitsh; Jia Hu; Catherine Hou; Luigi Grasso; Nicholas C Nicolaides; Vladimir R Muzykantov; Chaitanya R Divgi; George Coukos
Journal:  J Nucl Med       Date:  2014-02-13       Impact factor: 10.057

3.  Endosialin (Tem1) is a marker of tumor-associated myofibroblasts and tumor vessel-associated mural cells.

Authors:  Sven Christian; Renate Winkler; Iris Helfrich; Anja M Boos; Eva Besemfelder; Dirk Schadendorf; Hellmut G Augustin
Journal:  Am J Pathol       Date:  2008-01-10       Impact factor: 4.307

4.  Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature.

Authors:  John G Facciponte; Stefano Ugel; Francesco De Sanctis; Chunsheng Li; Liping Wang; Gautham Nair; Sandy Sehgal; Arjun Raj; Efthymia Matthaiou; George Coukos; Andrea Facciabene
Journal:  J Clin Invest       Date:  2014-03-18       Impact factor: 14.808

5.  The stromal cell antigen CD248 (endosialin) is expressed on naive CD8+ human T cells and regulates proliferation.

Authors:  Debbie L Hardie; Mathew J Baldwin; Amy Naylor; Oliver J Haworth; Tie Zheng Hou; Sian Lax; S John Curnow; Nick Willcox; John MacFadyen; Clare M Isacke; Christopher D Buckley
Journal:  Immunology       Date:  2011-04-06       Impact factor: 7.397

Review 6.  Characteristics of human Ewing/PNET sarcoma models.

Authors:  Beverly A Teicher; Rebecca G Bagley; Cecile Rouleau; Ariel Kruger; Yi Ren; Leslie Kurtzberg
Journal:  Ann Saudi Med       Date:  2011 Mar-Apr       Impact factor: 1.526

7.  Development of 89Zr-Ontuxizumab for in vivo TEM-1/endosialin PET applications.

Authors:  Sara E S Lange; Alex Zheleznyak; Matthew Studer; Daniel J O'Shannessy; Suzanne E Lapi; Brian A Van Tine
Journal:  Oncotarget       Date:  2016-03-15

Review 8.  CD248: A therapeutic target in cancer and fibrotic diseases.

Authors:  Beverly A Teicher
Journal:  Oncotarget       Date:  2019-01-29

9.  Hypoxia upregulates expression of human endosialin gene via hypoxia-inducible factor 2.

Authors:  A Ohradanova; K Gradin; M Barathova; M Zatovicova; T Holotnakova; J Kopacek; S Parkkila; L Poellinger; S Pastorekova; J Pastorek
Journal:  Br J Cancer       Date:  2008-09-23       Impact factor: 7.640

10.  Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: a new potential target for antifibrotic therapy.

Authors:  Paola Di Benedetto; Vasiliki Liakouli; Piero Ruscitti; Onorina Berardicurti; Francesco Carubbi; Noemi Panzera; Salvatore Di Bartolomeo; Giuliana Guggino; Francesco Ciccia; Giovanni Triolo; Paola Cipriani; Roberto Giacomelli
Journal:  Arthritis Res Ther       Date:  2018-10-03       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.